Hematology
A section of Current Oncology (ISSN 1718-7729).
Section Information
The Section Hematology of Current Oncology welcomes contemporary clinical, translational, and basic original research studies as well as review articles focusing on the treatment and diagnosis of hemato-oncological neoplasms—i.e., lymphomas, plasma cell disorders, chronic myeloid disorders (MDS, CMML, CML, MPNs), and acute leukemias. In particular, the journal welcomes articles on novel immunotherapeutic or targeted therapy approaches, and is interested in aspects of personalized therapeutic concepts. This refers to established therapeutic concepts as well as the development of new therapeutic strategies. Established and novel cellular therapies may also be considered.
Topics of interest in the fields of hematology and hemato-oncology:
- Clinical trials and registry-based studies as well as real-world studies;
- Pharmaco- and immunotherapeutic approaches;
- Review articles on treatment algorithms;
- Translational studies in the field of hematology and hemato-oncology;
- Basic research studies including preclinical animal model studies;
- Prognostication and outcome research;
- Personalized treatment concepts;
- Developments of diagnostics and their interaction with therapy;
- Education activities.
Editorial Board
Topical Advisory Panel
Special Issues
Following special issues within this section are currently open for submissions:
- Future Perspectives for Treatment and Diagnosis of Acute Myeloid Leukemia (AML) (Deadline: 1 March 2026)
- BCMA-Directed CAR-T Therapy in Relapsed or Refractory Multiple Myeloma (Deadline: 30 June 2026)
- 2nd Edition: Allogeneic Stem Cell Transplantation: Does the Conditioning Regimen Intensity Still Matter? (Deadline: 30 June 2026)
- Deep Insights into Acute Myeloid Leukemia: Molecular Targets and Evolving Treatment Paradigms (Deadline: 30 June 2026)
- Innovations in the Clinical Research of Chronic Myeloid Leukemia: From Targeted Therapies to Allogeneic Stem Cell Transplantation (Deadline: 31 July 2026)
- Hope Amidst Challenges: Therapies for Relapsed/Refractory Multiple Myeloma (Deadline: 10 August 2026)
- Clinical Progression and Treatment Outcome of Multiple Myeloma (Deadline: 15 November 2026)
- U.S. Myeloma Innovations Research Collaborative (USMIRC) Collection (Deadline: 31 December 2026)
